ArticleNature communications2026
Neoadjuvant chemotherapy interferes with tertiary lymphoid structure formation in Epstein-Barr virus-associated gastric cancer.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV)-associated gastric cancer (EBVaGC) is a molecularly distinct, highly immunogenic gastric cancer subtype, yet the role of tertiary lymphoid structure (TLS) during therapy remains unclear. Using a large locally advanced EBVaGC cohort (144 samples), combined with spatial transcriptomics (11 samples) and a single-cell atlas (77 samples), we show that EBVaGC exhibits enhanced TLS formation compared with EBV-negative gastric cancer, with invasive-margin TLS (IM-TLS) predicting favorable prognosis. Neoadjuvant chemotherapy disrupts TLS formation and shows limited efficacy in EBVaGC. Recurrent tumors display increased neutrophil infiltration around TLS, with aging neutrophils recruited via the CXCR4-CXCL12 axis. Mechanistically, chemotherapy induces EBV reactivation, activating neutrophil pattern recognition receptors and promoting neutrophil extracellular trap (NET) formation, which impairs lymphocyte migration and TLS maturation. These findings identify EBV reactivation-driven neutrophil aging and NET formation as a mechanism underlying poor prognosis in EBVaGC, positioning IM-TLS as a prognostic biomarker and neutrophil dysfunction as a therapeutic target.
Indexed as
Identifiers
42918766What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.